Real-world Outcomes of Facilitated Psilocybin Sessions under Oregon's Legal Framework

Clinical trials demonstrate psilocybin's efficacy for treatment-resistant depression and PTSD, but real-world outcomes from legal services remained unknown until now. This study provides the first systematic evidence from Oregon's supervised psilocybin program.We examined adults participating in psilocybin sessions at a licensed Oregon service center, measuring depression (PHQ-8), anxiety (GAD-7), and well-being (WHO-5) at baseline and 30 days post-session using validated assessments and linear mixed-effects modeling.

‍Key Findings: Among 88% Caucasian participants (47% female, mean age 47.3 years), significant improvements occurred across all domains. Depression scores decreased 4.6 points (moderate to mild severity), anxiety decreased 4.8 points (exceeding clinical significance thresholds), and well-being increased 10.7 points (meeting clinical significance for improved mood and quality of life).

‍Safety Profile: No reportable adverse events occurred, though 3% noted lingering negative effects at 30 days (anxiety, existential struggle, family coping difficulties).These real-world results align with clinical trial findings, providing preliminary evidence that Oregon's legal psilocybin sessions can significantly reduce depression and anxiety while enhancing well-being. This represents the first naturalistic evidence from legal U.S. psilocybin services, establishing crucial groundwork for understanding clinical trial translation as psychedelic medicine advances toward FDA approval.